150 related articles for article (PubMed ID: 36972765)
1. Disparities in Prostate Cancer Screening for Transgender Women: An Analysis of the MarketScan Database.
Premo H; Gordee A; Lee HJ; Scales CD; Moul JW; Peterson A
Urology; 2023 Jun; 176():237-242. PubMed ID: 36972765
[TBL] [Abstract][Full Text] [Related]
2. Prostate Cancer Screening Uptake in Transgender Women.
Kalavacherla S; Riviere P; Kalavacherla S; Anger JT; Murphy JD; Rose BS
JAMA Netw Open; 2024 Feb; 7(2):e2356088. PubMed ID: 38353948
[TBL] [Abstract][Full Text] [Related]
3. Prostate cancer in transgender women: what does a urologist need to know?
Bertoncelli Tanaka M; Sahota K; Burn J; Falconer A; Winkler M; Ahmed HU; Rashid TG;
BJU Int; 2022 Jan; 129(1):113-122. PubMed ID: 34157213
[TBL] [Abstract][Full Text] [Related]
4. Prostate-Specific Antigen Screening in Transgender Patients.
Nik-Ahd F; Jarjour A; Figueiredo J; Anger JT; Garcia M; Carroll PR; Cooperberg MR; Vidal AC; Freedland SJ
Eur Urol; 2023 Jan; 83(1):48-54. PubMed ID: 36344317
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of cancer risk factors among transgender and gender diverse individuals: a cross-sectional analysis using UK primary care data.
Brown J; Pfeiffer RM; Shrewsbury D; O'Callaghan S; Berner AM; Gadalla SM; Shiels MS; Jackson SS
Br J Gen Pract; 2023 Jul; 73(732):e486-e492. PubMed ID: 37365010
[TBL] [Abstract][Full Text] [Related]
6. Prostate Cancer Screening Patterns Among Sexual and Gender Minority Individuals.
Ma SJ; Oladeru OT; Wang K; Attwood K; Singh AK; Haas-Kogan DA; Neira PM
Eur Urol; 2021 May; 79(5):588-592. PubMed ID: 33250303
[TBL] [Abstract][Full Text] [Related]
7. Use of the prostate-specific antigen test in the U.S. for men age 30 to 64 in 2011 to 2017 using a large commercial claims database: Implications for practice interventions.
Shahangian S; Sharma KP; Fan L; Siegel DA
Cancer Rep (Hoboken); 2021 Aug; 4(4):e1365. PubMed ID: 33934557
[TBL] [Abstract][Full Text] [Related]
8. Gender Identity Disparities in Cancer Screening Behaviors.
Tabaac AR; Sutter ME; Wall CSJ; Baker KE
Am J Prev Med; 2018 Mar; 54(3):385-393. PubMed ID: 29338956
[TBL] [Abstract][Full Text] [Related]
9. Prostate Cancer in Male-to-Female Transgender Individuals: Histopathologic Findings and Association With Gender-affirming Hormonal Therapy.
Baraban E; Ding CC; White M; Vohra P; Simko J; Boyle K; Guo C; Zhang M; Dobs A; Ketheeswaran S; Liang F; Epstein JI
Am J Surg Pathol; 2022 Dec; 46(12):1650-1658. PubMed ID: 36006769
[TBL] [Abstract][Full Text] [Related]
10. PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening.
Kearns JT; Holt SK; Wright JL; Lin DW; Lange PH; Gore JL
Cancer; 2018 Jul; 124(13):2733-2739. PubMed ID: 29781117
[TBL] [Abstract][Full Text] [Related]
11. Prostate Cancer in Transgender Women: Epidemiology, Clinical Characteristics, and Management Challenges.
Manfredi C; Ditonno F; Franco A; Bologna E; Licari LC; Arcaniolo D; Tubaro A; De Nunzio C; Antonelli A; De Sio M; Cherullo EE; Autorino R
Curr Oncol Rep; 2023 Dec; 25(12):1431-1443. PubMed ID: 37910274
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen testing rates in high-risk populations: results from the All of Us Research Program.
Morley F; Iyer HS; Tamimi RM; Nanus DM; Rebbeck TR; Kensler KH
Cancer Causes Control; 2024 Mar; 35(3):509-521. PubMed ID: 37878135
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer is not just a man's concern - the use of PSA screening in transgender women.
Nik-Ahd F; Anger JT; Cooperberg MR; Freedland SJ
Nat Rev Urol; 2023 Jun; 20(6):323-324. PubMed ID: 37217694
[No Abstract] [Full Text] [Related]
14. Suicidal Ideation Disparities Among Transgender and Gender Diverse Compared to Cisgender Community Health Patients.
Kirakosian N; Stanton AM; McKetchnie SM; King D; Dolotina B; O'Cleirigh C; Grasso C; Potter J; Mayer KH; Batchelder AW
J Gen Intern Med; 2023 May; 38(6):1357-1365. PubMed ID: 36650322
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer screening practices in a large, integrated health system: 2007-2014.
Misra-Hebert AD; Hu B; Klein EA; Stephenson A; Taksler GB; Kattan MW; Rothberg MB
BJU Int; 2017 Aug; 120(2):257-264. PubMed ID: 28139034
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen (PSA) screening and follow-up investigations in Māori and non-Māori men in New Zealand.
Obertová Z; Scott N; Brown C; Hodgson F; Stewart A; Holmes M; Lawrenson R
BMC Fam Pract; 2014 Aug; 15():145. PubMed ID: 25154420
[TBL] [Abstract][Full Text] [Related]
17. Contemporary National Trends of Prostate Cancer Screening Among Privately Insured Men in the United States.
Kim SP; Karnes RJ; Gross CP; Meropol NJ; Van Houten H; Abouassaly R; Shah ND
Urology; 2016 Nov; 97():111-117. PubMed ID: 27527411
[TBL] [Abstract][Full Text] [Related]
18. Analysis of Mortality Among Transgender and Gender Diverse Adults in England.
Jackson SS; Brown J; Pfeiffer RM; Shrewsbury D; O'Callaghan S; Berner AM; Gadalla SM; Shiels MS
JAMA Netw Open; 2023 Jan; 6(1):e2253687. PubMed ID: 36716027
[TBL] [Abstract][Full Text] [Related]
19. Disparities in health condition diagnoses among aging transgender and cisgender medicare beneficiaries, 2008-2017.
Hughto JMW; Varma H; Babbs G; Yee K; Alpert A; Hughes L; Ellison J; Downing J; Shireman TI
Front Endocrinol (Lausanne); 2023; 14():1102348. PubMed ID: 36992801
[TBL] [Abstract][Full Text] [Related]
20. Prostate cancer in transgender women.
Ingham MD; Lee RJ; MacDermed D; Olumi AF
Urol Oncol; 2018 Dec; 36(12):518-525. PubMed ID: 30322726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
